Exclusive partnership for cancer assay

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed an exclusive distribution agreement with Curesponse Ltd ("Curesponse"), to market the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark.

cResponse™ is a groundbreaking platform that biologically assesses how an individual patient's living tumour tissue responds to selected medicines, identifying the most effective treatment options. It is the only clinical-grade technology providing biological response data for chemotherapy, targeted biologics, and immunotherapy drugs. This platform helps clinicians rapidly pinpoint optimal treatments, potentially saving lives, reducing treatment costs, and accelerating the discovery and development cycles for pharmaceutical companies seeking new cancer drugs.

The cResponse™ platform generates a report ranking selected cancer drugs based on their predicted effect on an individual patient's tumour, demonstrating over 90% accuracy in clinical trials. The test can be augmented with rapid genomic sequencing to identify additional drug candidates for functional analysis. The entire process is powered by proprietary technologies and advanced AI algorithms. The platform technology has been refined and calibrated using thousands of cancer tissues, demonstrating its clinical utility and effectiveness through hundreds of cases in Israel and the UK. The cResponse™ test is performed at a United Kingdom Accreditation Service (UKAS) accredited lab in London and has also earned a CE mark for Europe, underscoring its regulatory approval and readiness for clinical use.

EDX Medical will initiate commercial activities to support the clinical use of the cResponse™ assay in the UK and Nordics with immediate effect and will explore broadening the agreement with Curesponse in due course.

Professor Sir Chris Evans, OBE, founder of EDX Medical plc, commented: "We are delighted to be increasing accessibility to this genuinely innovative and pioneering test which potentially offers tremendous benefit to those treating cancer and their patients. This product is an excellent addition to our rapidly growing portfolio of class-leading diagnostic solutions."

Dr Mike Hudson, CEO, EDX Medical plc, said: "We are very pleased to have been selected by Curesponse as their partner, and to be able to make their breakthrough assay available for our clients in the UK and Nordics. We consider cResponse™ to be an outstanding innovation in the fast-moving clinical cancer diagnostic landscape."

Guy Neev, CEO of Curesponse Ltd, commented: "We are thrilled to partner with EDX Medical Group to bring our cResponse™ platform to patients and clinicians in the UK and Nordic countries. Our mission at Curesponse is to make this technology available to cancer patients to optimize treatment outcomes and save lives. This collaboration is a significant step toward achieving that goal. We look forward to working closely with the EDX Medical team to ensure the successful adoption and implementation of this groundbreaking decision support tool."

The Board of directors of EDX Medical plc accepts responsibility for this announcement.

About Curesponse Ltd

Curesponse is a pioneering leader in precision oncology. Founded on extensive research originating from the esteemed Weizmann Institute of Science on the Tumour-Micro-Environment, and supported by impactful publications, Curesponse is transforming the landscape of cancer care and oncology drug development.

The company has developed a Personal Derived Explants (PDE) platform, with the ability to accurately predict human responses to a diverse range of cancer therapies and oncology drug candidates with an unprecedented accuracy rate. This platform enables personalised matching with the most suitable drug from the outset, maximizing the likelihood of a favourable response, reducing unnecessary treatments, and generating cost savings for healthcare systems.

The company operates accredited labs in Israel and in the UK at the London Cancer Hub. and has landmarked a CE mark for Europe and granted patents for EU and US, in its expansion roadmap.